Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Christian Angermayer, the chairman of Germany-based biopharmaceutical company atai Life Sciences (ATAI) announced today that the firm would develop its own bitcoin treasury strategy.
“In an era of persistent inflation and volatile markets, I find myself asking an important question for biotech companies looking to preserve and optimize the capital they have: Could allocating a portion of treasury cash to bitcoin help preserve, optimize, and even extend a company’s runway and hence contribute to its success,” Angermayer wrote on Substack.
The company will initially invest $5 million in bitcoin, Angermayer said, while holding enough cash, short-term securities and public equity for operational expenses into 2027.
#TUT Price Rise
#Crypto ETFs Under Application